Clinical Trial Update: Posterior Vitreous Detachment (PVD) Assessment During Dual Retinal Vein Occlusion (RVO) Lucentis Evaluations [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ranibizumab (Lucentis) for retinal vein occlusion, with assessment of posterior vitreous detachment, is reported as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Posterior Vitreous Detachment
• Retinal Vein Occlusion

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Barnes Retina Institute | Conditions: Retinal Vein Occlusion, Posterior Vitreous Detachment | Phase 2 | Status: COMPLETED